HIGHLIGHTS

• 13 year drug discovery experience: both big pharma and biotech
• Successful track record: multiple INDs and clinical trial compounds
• Success in both traditional medicinal chemistry and SBDD
• Experience with multiple therapeutic areas: antiviral, oncology, inflammation and CNS
• Experience with multiple target classes: GPCR, kinase and nuclear receptor
• Substantial intellectual property management experience
• Patent application drafting and prosecution experience
• Proven strategic and project management skills
• Proven external collaboration management skills
• Proven people management skills
• Business development and portfolio management experience
• Author or co-author of over 40 publications, inventor and patent holder

RESEARCH AND PROFESSIONAL EXPERIENCE

***** Consulting, ***** La Jolla, CA
Founder and President 03/2008-Current
Consulting area: Strategic planning, Medicinal Chemistry Research, Project Development and Management, Outsourcing, Project Evaluation and Intellectual Property Evaluation
Consultancies:
• Zenobia Therapeutics, La Jolla, CA: Board member, secure grant funding, success in outsourcing, lead optimization, IP strategy
• Orphagen Pharmaceuticals, San Diego, CA: Management team, secure grant funding, maintain successful collaboration with partners and CROs, lead optimization, IP strategy
• LEAD Therapeutics, San Bruno, CA: Project evaluations led to timely decision making
• TechLaw LLP, San Diego, CA: Technical assistance in patent prosecution
• CalAsia Pharmaceuticals, San Diego, CA: Project evaluations
• Arisan Therapeutics, San Diego, CA: Project evaluations, grant application

SGX Pharmaceuticals, ***** San Diego, CA
Director, Medicinal Chemistry 07/ ***** /2008
Associate Director, Medicinal Chemistry 11/ ***** /2006
• Two INDs and one clinical trial compound
• Project leader (25 people project team)
• Medicinal chemistry department management (15 chemists)
• Research portfolio management (kinase targets for oncology)
• Intellectual property management
• Assisted business development activities
• A member of the Research Leadership Committee
• A member of the Employee Recognition Committee

Genomics Institute of the Novartis Research Foundation, San Diego, CA
Senior Principal Investigator 06/ ***** /2004
• Advanced two compounds into toxicity studies
• Project management (kinase targets)
• People management (8 chemists)

Schering-Plough Research Institute, Kenilworth, New Jersey
Associate Principal Scientist 07/ ***** /2002
Senior Scientist 12/ ***** /2000
• Key player in moving two CCR5 antagonists into clinical trials, one of which in phase III currently
• Designed and synthesized novel chemical entities for optimal biological activity and pharmacokinetic profile
• People and database management

EDUCATION

University of Pennsylvania, Philadelphia, Pennsylvania
Post-doctoral Research Fellow, 1997
The Scripps Research Institute, La Jolla, California ***** anic Chemistry, 1995
Peking University, Beijing, China
B. S. Chemistry, 1989

CONTINUING EDUCATION

• Residential School on Medicinal Chemistry-Madison, NJ 1999
• Training for Managers-Kenilworth, NJ 2000
• Pharmacokinetics and Pharmacodynamics-Kenilworth, NJ 2001
• Medicinal Chemistry Certificate Program-San Diego, CA 2003
• Heterocycle Chemistry-San Diego, CA 2003
• Toxicology: Principles and Applications-San Francisco, CA 2004
• Drug-like Properties in Drug Discovery-San Diego, CA 2005
• The Leadership Edge-San Diego, CA 2006
• Pharmacokinetics and Pharmacodynamics-Boston, MA 2006
• Managing Technical Professionals & Organizations, MIT Sloan School of Management-Boston, MA 2007


AFFILIATIONS

American Chemical Society, Members-at-Large, San Diego Section
American Association of Pharmaceutical Scientists
ATHENA, FEW Steering Committee Member
Sino-American Biomedical & Pharmaceutical Professionals Association
San Diego Entrepreneur Exchange, Executive Committee Member

AWARDS

Schering-Plough Research Institute, Kenilworth, New Jersey 2000
President’s award for outstanding scientific and technical achievement in the discovery of CCR5 receptor antagonists as therapeutic agents for the treatment of HIV infection

Thomas Alva Edison Patent Award, Edison, New Jersey 2004
U. S. patent 6, 87, 30 “Piperidine Derivatives Useful as CCR5 Antagonists”

ACS Innovative Project Grant Award, Washington, D. C. 2010
Granted to ACS-San Diego Section based on proposal entitled “From Bench to CEO: What do you need to know if you want to become an entrepreneur?”